Sg Americas Securities, LLC Inhibrx, Inc. Transaction History

Sg Americas Securities, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	BUY	$18.45 - $27.14 $199,702 - $293,763	10,824 Added 249.46%	15,163 $286,000
Q4 2022 Feb 02, 2023	SELL	$20.18 - $33.33 $36,727 - $60,660	-1,820 Reduced 29.55%	4,339 $107,000
Q3 2022 Oct 31, 2022	BUY	$11.58 - $24.73 $71,321 - $152,312	6,159 New	6,159 $111,000
Q1 2022 Apr 29, 2022	SELL	$19.89 - $43.18 $118,842 - $258,000	-5,975 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$26.75 - $46.02 $125,618 - $216,109	-4,696 Reduced 44.01%	5,975 $261,000
Q3 2021 Nov 01, 2021	BUY	$25.18 - $37.81 $268,695 - $403,470	10,671 New	10,671 $355,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.